Pub Date : 2024-07-01Epub Date: 2024-06-07DOI: 10.1080/07357907.2024.2361305
Ratnakar Shukla, Yasuo Tsuchiya, Anu Behari, Toshikazu Ikoma, Kazutoshi Nakamura, Vinay K Kapoor
Biliary dysbiosis is associated with gallbladder cancer (GBC). We aimed to look for biliary bacteria specifically detected in GBC patients. We used 16S rRNA-based metagenomic analysis to elucidate biliary microbiota in 30 GBC and 30 gallstones-associated chronic cholecystitis patients. Relative abundance of five genera, Streptococcus, Enterococcus, Halomonas, Escherichia and Caulobacter was significantly associated with GBC. Of 15-species, 7 were detected significantly higher in GBC, Streptococcus anginosus, Streptococcus constellatus, Streptococcus intermedius, Actinomyces bowdenii, Actinomyces israelii, Actinomyces gerencseriae, and Escherichia fergusonii were biosafety level-2 infectious bacteria; other 8 species were biosafety level-1 bacteria. These bacterial species may be involved in pathogenesis of GBC.
{"title":"Metagenomic Analysis of Biliary Microbial Flora in Patients with Gallbladder Cancer or Gallstones-Associated Chronic Cholecystitis.","authors":"Ratnakar Shukla, Yasuo Tsuchiya, Anu Behari, Toshikazu Ikoma, Kazutoshi Nakamura, Vinay K Kapoor","doi":"10.1080/07357907.2024.2361305","DOIUrl":"10.1080/07357907.2024.2361305","url":null,"abstract":"<p><p>Biliary dysbiosis is associated with gallbladder cancer (GBC). We aimed to look for biliary bacteria specifically detected in GBC patients. We used 16S rRNA-based metagenomic analysis to elucidate biliary microbiota in 30 GBC and 30 gallstones-associated chronic cholecystitis patients. Relative abundance of five genera, <i>Streptococcus, Enterococcus</i>, <i>Halomonas</i>, <i>Escherichia</i> and <i>Caulobacter</i> was significantly associated with GBC. Of 15-species, 7 were detected significantly higher in GBC, <i>Streptococcus anginosus</i>, <i>Streptococcus constellatus</i>, <i>Streptococcus intermedius, Actinomyces bowdenii</i>, <i>Actinomyces israelii</i>, <i>Actinomyces gerencseriae</i>, and <i>Escherichia fergusonii</i> were biosafety level-2 infectious bacteria; other 8 species were biosafety level-1 bacteria. These bacterial species may be involved in pathogenesis of GBC.</p>","PeriodicalId":9463,"journal":{"name":"Cancer Investigation","volume":" ","pages":"478-490"},"PeriodicalIF":1.8,"publicationDate":"2024-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141282997","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
We examined Fusobacterium nucreatum (F. nucleatum) and whole Fusobacterium species (Pan-fusobacterium) in non-neoplastic Barrett's esophagus (BE) from patients without cancer (n = 67; N group), with esophageal adenocarcinoma (EAC) (n = 27) and EAC tissue (n = 22). F. nucleatum was only detectable in 22.7% of EAC tissue. Pan-fusobacterium was enriched in EAC tissue and associated with aggressive clinicopathological features. Amount of Pan-fusobacterium in non-neoplastic BE was correlated with presence of hital hernia and telomere shortening. The result suggested potential association of Fusobacterium species in EAC and BE, featuring clinicpathological and molecular features.
{"title":"Fusobacterium Detected in Barrett's Esophagus and Esophageal Adenocarcinoma Tissues.","authors":"Tomomitsu Tahara, Takuya Shijimaya, Jumpei Yamazaki, Sanshiro Kobayashi, Anna Horitani, Yasushi Matsumoto, Naohiro Nakamura, Takashi Okazaki, Yu Takahashi, Takashi Tomiyama, Yusuke Honzawa, Norimasa Fukata, Toshiro Fukui, Makoto Naganuma","doi":"10.1080/07357907.2024.2359980","DOIUrl":"10.1080/07357907.2024.2359980","url":null,"abstract":"<p><p>We examined <i>Fusobacterium nucreatum</i> (<i>F. nucleatum</i>) and whole <i>Fusobacterium species</i> (<i>Pan-fusobacterium</i>) in non-neoplastic Barrett's esophagus (BE) from patients without cancer (<i>n</i> = 67; N group), with esophageal adenocarcinoma (EAC) (<i>n</i> = 27) and EAC tissue (<i>n</i> = 22). <i>F. nucleatum</i> was only detectable in 22.7% of EAC tissue. <i>Pan-fusobacterium</i> was enriched in EAC tissue and associated with aggressive clinicopathological features. Amount of <i>Pan-fusobacterium</i> in non-neoplastic BE was correlated with presence of hital hernia and telomere shortening. The result suggested potential association of <i>Fusobacterium species</i> in EAC and BE, featuring clinicpathological and molecular features.</p>","PeriodicalId":9463,"journal":{"name":"Cancer Investigation","volume":" ","pages":"469-477"},"PeriodicalIF":1.8,"publicationDate":"2024-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141445691","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
This meta-analysis evaluated the impact of prophylactic post-chemotherapy granulocyte colony-stimulating factor (G-CSF) in patients with acute myeloid leukemia (AML). Overall, the relapse rate, overall survival, event-free survival, and mortality rate were similar in G-CSF (+) compared to G-CSF (-) patients. However, the relative risk (RR) of relapse was higher in children and in secondary AML patients who were treated with G-CSF compared to the G-CSF (-) group [RR, 95% confidence interval: 1.26, 1.04-1.52, and 1.12 (1.02-1.24)]. Treatment with post-chemotherapy G-CSF should be prescribed with caution in pediatric patients with AML and secondary AML as possibly increasing the relapse risk.
{"title":"The Impact of Prophylactic Post-Chemotherapy G-CSF on the Relapse Rates in Patients with Acute Myeloid Leukemia: A Meta-Analysis.","authors":"Mohammadreza Bordbar, Mahnaz Hosseini-Bensenjan, Mehrab Sayadi, Omidreza Zekavat, Shayan Bordbar, Farnoosh Nozari, Sezaneh Haghpanah","doi":"10.1080/07357907.2024.2352454","DOIUrl":"10.1080/07357907.2024.2352454","url":null,"abstract":"<p><p>This meta-analysis evaluated the impact of prophylactic post-chemotherapy granulocyte colony-stimulating factor (G-CSF) in patients with acute myeloid leukemia (AML). Overall, the relapse rate, overall survival, event-free survival, and mortality rate were similar in G-CSF (+) compared to G-CSF (-) patients. However, the relative risk (RR) of relapse was higher in children and in secondary AML patients who were treated with G-CSF compared to the G-CSF (-) group [RR, 95% confidence interval: 1.26, 1.04-1.52, and 1.12 (1.02-1.24)]. Treatment with post-chemotherapy G-CSF should be prescribed with caution in pediatric patients with AML and secondary AML as possibly increasing the relapse risk.</p>","PeriodicalId":9463,"journal":{"name":"Cancer Investigation","volume":" ","pages":"452-468"},"PeriodicalIF":1.8,"publicationDate":"2024-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141449755","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-07-01Epub Date: 2024-05-22DOI: 10.1080/07357907.2024.2354991
Gary H Lyman, Nicole M Kuderer
{"title":"Artificial Intelligence in Cancer Clinical Research: II. Development and Validation of Clinical Prediction Models.","authors":"Gary H Lyman, Nicole M Kuderer","doi":"10.1080/07357907.2024.2354991","DOIUrl":"10.1080/07357907.2024.2354991","url":null,"abstract":"","PeriodicalId":9463,"journal":{"name":"Cancer Investigation","volume":" ","pages":"447-451"},"PeriodicalIF":1.8,"publicationDate":"2024-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141075438","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-07-01Epub Date: 2024-07-02DOI: 10.1080/07357907.2024.2366907
Sandra B Amado-Garzon, Luisana Molina-Pimienta, Andrea Vejarano-Pombo, Mariana Vélez-Bonilla, Jaime Moreno-Chaparro, Adriana Buitrago-Lopez
Vitamin B12 (B12) is a molecule involved in several biological. Abnormally high levels are frequently found, but their causes can be multiple, and consequences have not been clearly elucidated. The objective of this review was to summarize the current evidence on the associations of elevated B12 and the development of cancer, and all-cause mortality in adults. Six references looking at mortality and seven looking at cancer risk were included. The evidence suggests an association between elevated B12 with a higher risk of cancer, with risk ratios ranging 1,88 to 5,9. There was less consistent evidence linking vitamin B12 and mortality.
{"title":"Elevated Vitamin B12, Risk of Cancer, and Mortality: A Systematic Review.","authors":"Sandra B Amado-Garzon, Luisana Molina-Pimienta, Andrea Vejarano-Pombo, Mariana Vélez-Bonilla, Jaime Moreno-Chaparro, Adriana Buitrago-Lopez","doi":"10.1080/07357907.2024.2366907","DOIUrl":"10.1080/07357907.2024.2366907","url":null,"abstract":"<p><p>Vitamin B12 (B12) is a molecule involved in several biological. Abnormally high levels are frequently found, but their causes can be multiple, and consequences have not been clearly elucidated. The objective of this review was to summarize the current evidence on the associations of elevated B12 and the development of cancer, and all-cause mortality in adults. Six references looking at mortality and seven looking at cancer risk were included. The evidence suggests an association between elevated B12 with a higher risk of cancer, with risk ratios ranging 1,88 to 5,9. There was less consistent evidence linking vitamin B12 and mortality.</p>","PeriodicalId":9463,"journal":{"name":"Cancer Investigation","volume":" ","pages":"515-526"},"PeriodicalIF":1.8,"publicationDate":"2024-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141490966","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-07-01Epub Date: 2024-06-18DOI: 10.1080/07357907.2024.2363879
Yinghan Zeng, Chengna Cai, Nafen Pan
Sarcopenia can negatively impact the survival of cancer patients. This study intends to delve into the correlation of sarcopenia with survival and complications in patients with bladder cancer (BC) after surgery. Web of Science, Cochrane Library, Embase, and PubMed databases were retrieved up to April 7, 2023, to collect studies on the impact of sarcopenia on the prognosis of adults with BC. Primary outcomes encompassed overall survival (OS), cancer-specific survival (CSS), and recurrence-free survival (RFS). The secondary outcome consisted of postoperative complications. A meta-analysis was conducted using Stata. Forest plots and summary effect models were employed to present the results. The quality of eligible studies was assessed using the Newcastle-Ottawa Scale (NOS). Initially, 1713 studies were identified through searches across four databases, and 26 studies were ultimately included in the analysis. Sarcopenia was significantly associated with OS (HR:1.62; 95% CI: 1.43-1.83; P < 0.001, I2 = 0.9%), CSS (HR: 1.81, 95% CI: 1.52-2.15, P < 0.001, I2 = 0.0%), and RFS (HR: 1.76, 95% CI: 1.21-2.56, P = 0.003, I2 = 0.0%) in BC patients. Subgroup analyses revealed that sarcopenia is strongly linked to prognosis and postoperative complications in BC patients.
肌肉疏松症会对癌症患者的生存产生负面影响。本研究旨在探讨肌肉疏松症与膀胱癌(BC)患者术后生存期及并发症的相关性。本研究检索了截至 2023 年 4 月 7 日的 Web of Science、Cochrane Library、Embase 和 PubMed 数据库,以收集有关肌肉疏松症对成年 BC 患者预后影响的研究。主要结果包括总生存期(OS)、癌症特异性生存期(CSS)和无复发生存期(RFS)。次要结果包括术后并发症。使用 Stata 进行了荟萃分析。采用森林图和摘要效应模型来呈现结果。采用纽卡斯尔-渥太华量表(Newcastle-Ottawa Scale,NOS)对符合条件的研究进行质量评估。通过在四个数据库中搜索,初步确定了 1713 项研究,最终有 26 项研究被纳入分析。在 BC 患者中,肌肉疏松症与 OS(HR:1.62;95% CI:1.43-1.83;P I2 = 0.9%)、CSS(HR:1.81;95% CI:1.52-2.15;P I2 = 0.0%)和 RFS(HR:1.76;95% CI:1.21-2.56;P = 0.003;I2 = 0.0%)明显相关。亚组分析显示,肌少症与 BC 患者的预后和术后并发症密切相关。
{"title":"Prognostic Effects of Sarcopenia on Patients with Bladder Cancer: A Systematic Review and Meta-Analysis.","authors":"Yinghan Zeng, Chengna Cai, Nafen Pan","doi":"10.1080/07357907.2024.2363879","DOIUrl":"10.1080/07357907.2024.2363879","url":null,"abstract":"<p><p>Sarcopenia can negatively impact the survival of cancer patients. This study intends to delve into the correlation of sarcopenia with survival and complications in patients with bladder cancer (BC) after surgery. Web of Science, Cochrane Library, Embase, and PubMed databases were retrieved up to April 7, 2023, to collect studies on the impact of sarcopenia on the prognosis of adults with BC. Primary outcomes encompassed overall survival (OS), cancer-specific survival (CSS), and recurrence-free survival (RFS). The secondary outcome consisted of postoperative complications. A meta-analysis was conducted using Stata. Forest plots and summary effect models were employed to present the results. The quality of eligible studies was assessed using the Newcastle-Ottawa Scale (NOS). Initially, 1713 studies were identified through searches across four databases, and 26 studies were ultimately included in the analysis. Sarcopenia was significantly associated with OS (HR:1.62; 95% CI: 1.43-1.83; <i>P</i> < 0.001, <i>I</i><sup>2</sup> = 0.9%), CSS (HR: 1.81, 95% CI: 1.52-2.15, <i>P</i> < 0.001, <i>I</i><sup>2</sup> = 0.0%), and RFS (HR: 1.76, 95% CI: 1.21-2.56, <i>P</i> = 0.003, <i>I</i><sup>2</sup> = 0.0%) in BC patients. Subgroup analyses revealed that sarcopenia is strongly linked to prognosis and postoperative complications in BC patients.</p>","PeriodicalId":9463,"journal":{"name":"Cancer Investigation","volume":" ","pages":"500-514"},"PeriodicalIF":1.8,"publicationDate":"2024-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141417943","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-07-01Epub Date: 2024-06-21DOI: 10.1080/07357907.2024.2368233
Dan Liu, Jiang Zhou, Qiong Fu, Yuanzhu Zhao, Panpan Wang, Yang Zheng, Meihong Cui, Heng Zhang
Objective: The composition of microbiota which correlates with infiltrating immune cells and clinical signatures is not clarified in CRC.
Methods: We applied 4 kinds of bioinformatic tools GSVA (version: 1.42.0), ESTIMATE (version: 1.0.13), CIBERSORT (version: 2.0), and immune-related genes.
Results: We found that a total of 8 types of microbiotas appeared in the three immune correlation analyses. Among these microbiotas, significant enrichments in relative abundances associated with immune cell infiltration can be found for the dominant phyla Proteobacteria, Firmicutes, and Actinobacteria. Moreover, there existed correlations between some of the 8 microbiotas and clinical-related indicators.
Conclusion: We identified some novel microbiotas involved in immune regulation in CRC.
{"title":"A Bioinformatic Analysis of Gut Microbiota Related with Immune Cell Infiltration in Colorectal Cancer.","authors":"Dan Liu, Jiang Zhou, Qiong Fu, Yuanzhu Zhao, Panpan Wang, Yang Zheng, Meihong Cui, Heng Zhang","doi":"10.1080/07357907.2024.2368233","DOIUrl":"10.1080/07357907.2024.2368233","url":null,"abstract":"<p><strong>Objective: </strong>The composition of microbiota which correlates with infiltrating immune cells and clinical signatures is not clarified in CRC.</p><p><strong>Methods: </strong>We applied 4 kinds of bioinformatic tools GSVA (version: 1.42.0), ESTIMATE (version: 1.0.13), CIBERSORT (version: 2.0), and immune-related genes.</p><p><strong>Results: </strong>We found that a total of 8 types of microbiotas appeared in the three immune correlation analyses. Among these microbiotas, significant enrichments in relative abundances associated with immune cell infiltration can be found for the dominant phyla Proteobacteria, Firmicutes, and Actinobacteria. Moreover, there existed correlations between some of the 8 microbiotas and clinical-related indicators.</p><p><strong>Conclusion: </strong>We identified some novel microbiotas involved in immune regulation in CRC.</p>","PeriodicalId":9463,"journal":{"name":"Cancer Investigation","volume":" ","pages":"491-499"},"PeriodicalIF":1.8,"publicationDate":"2024-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141436399","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-07-01Epub Date: 2024-07-05DOI: 10.1080/07357907.2024.2366912
Wei-Na Yang, Xue-Mei Li, Chao-Fan Li, Chuan Chen, Yan Feng, Nan Dai, Yu-Xin Yang, Meng-Xia Li, Chun-Xue Li, Cheng-Yuan Qian, Dong Wang, He Xiao, Jia-Min Luo
Despite the emergence of various treatment strategies for rectal cancer based on neoadjuvant chemoradiotherapy, there is currently a lack of reliable biomarkers to determine which patients will respond well to neoadjuvant chemoradiotherapy. Through collecting hematological and biochemical parameters data of patients prior to receiving neoadjuvant chemoradiotherapy, we evaluated the predictive value of systemic inflammatory indices for pathological response and prognosis in rectal cancer patients. We found that baseline GRIm-Score was an independent predictor for MPR in rectal cancer patients. However, no association was observed between several commonly systemic inflammation indices and long-term outcome.
{"title":"Gustative Roussy Immune Score is a Predictor for Major Pathological Response in Rectal Cancer: A Result from the Preoperative Intraarterial Chemoembolization Combined with Radiotherapy (PCAR) Study.","authors":"Wei-Na Yang, Xue-Mei Li, Chao-Fan Li, Chuan Chen, Yan Feng, Nan Dai, Yu-Xin Yang, Meng-Xia Li, Chun-Xue Li, Cheng-Yuan Qian, Dong Wang, He Xiao, Jia-Min Luo","doi":"10.1080/07357907.2024.2366912","DOIUrl":"10.1080/07357907.2024.2366912","url":null,"abstract":"<p><p>Despite the emergence of various treatment strategies for rectal cancer based on neoadjuvant chemoradiotherapy, there is currently a lack of reliable biomarkers to determine which patients will respond well to neoadjuvant chemoradiotherapy. Through collecting hematological and biochemical parameters data of patients prior to receiving neoadjuvant chemoradiotherapy, we evaluated the predictive value of systemic inflammatory indices for pathological response and prognosis in rectal cancer patients. We found that baseline GRIm-Score was an independent predictor for MPR in rectal cancer patients. However, no association was observed between several commonly systemic inflammation indices and long-term outcome.</p>","PeriodicalId":9463,"journal":{"name":"Cancer Investigation","volume":" ","pages":"527-537"},"PeriodicalIF":1.8,"publicationDate":"2024-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141533682","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-05-02DOI: 10.1080/07357907.2024.2345183
Morvarid Soleiman, Mehrnoosh Fathi-Roudsari, Khosro Khajeh, Amir Maghsoudi
Glioblastoma multiforme (GBM), is a frequent class of malignant brain tumors. Epigenetic therapy, especially with synergistic combinations is highly paid attention for aggressive solid tumors like ...
{"title":"Optimization of Epigenetic Modifier Drug Combination for Synergistic Effect against Glioblastoma Multiform Cancer Cell Lines","authors":"Morvarid Soleiman, Mehrnoosh Fathi-Roudsari, Khosro Khajeh, Amir Maghsoudi","doi":"10.1080/07357907.2024.2345183","DOIUrl":"https://doi.org/10.1080/07357907.2024.2345183","url":null,"abstract":"Glioblastoma multiforme (GBM), is a frequent class of malignant brain tumors. Epigenetic therapy, especially with synergistic combinations is highly paid attention for aggressive solid tumors like ...","PeriodicalId":9463,"journal":{"name":"Cancer Investigation","volume":"30 1","pages":""},"PeriodicalIF":2.4,"publicationDate":"2024-05-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140829478","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-05-02DOI: 10.1080/07357907.2024.2347784
Gary H. Lyman, Nicole M. Kuderer
Published in Cancer Investigation (Ahead of Print, 2024)
发表于《癌症调查》(2024 年提前出版)
{"title":"Artificial Intelligence in Cancer Clinical Research: I. Introduction","authors":"Gary H. Lyman, Nicole M. Kuderer","doi":"10.1080/07357907.2024.2347784","DOIUrl":"https://doi.org/10.1080/07357907.2024.2347784","url":null,"abstract":"Published in Cancer Investigation (Ahead of Print, 2024)","PeriodicalId":9463,"journal":{"name":"Cancer Investigation","volume":"20 1","pages":""},"PeriodicalIF":2.4,"publicationDate":"2024-05-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140829752","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}